Suggestions
Weiyong Sun
Chief Business Officer at Hansoh Bio/Hansoh Pharma
Weiyong Sun is a highly accomplished and respected pharmaceutical industry veteran, with extensive experience in drug development, external scientific affairs, and global business development and licensing. With over 13 years of experience as a successful in-licensing projects developer and business partnership manager, he has built strong and trusted relationships with numerous venture capital firms and biotech companies worldwide. Dr. Sun is well-versed in cardiovascular metabolic and autoimmune disorders and currently serves as the Senior Director for Specialty Medicine Search & Evaluation, Global Business Development at Daiichi Sankyo, Inc, where he is responsible for identifying and developing new CNS, Immunology, and Rare Diseases therapeutic areas. He is a skilled negotiator and communicator, fluent in Japanese, Chinese, and English. Dr. Sun has a rich educational background, including a Doctor of Medicine (M.D.), Clinical Medicine from Peking University and a Ph.D. in Biochemistry from The University of Tokyo. He has also completed a Stanford Advanced Project Management Certificate Program and an MBA specializing in Accounting, Corporate Finance, Leadership, and Strategy at Columbia University's Business School. During his free time, he enjoys wine tasting, a hobby that underscores his attention to detail and exceptional taste.
Highlights
Today, Hansoh Pharma announced another exciting new licensing agreement with GSK for HS-20093, our in-house novel B7H3 ADC, following an earlier agreement for our HS-20089, B7H4ADC. HS-20093 has shown promising initial clinical activity in lung cancer with the potential to address unmet medical needs in broader solid tumor indications. Under the terms of the new agreement, Hansoh will receive an upfront payment of $185 million and will be eligible to receive milestone payments of up to $1.525 billion. Both GSK and Hansoh are happy with our existing collaboration on HS-20089 and decided to expand our collaboration to HS-20093. It highlights the excellence of Hansoh’s novel discovery capabilities, as well as our Board’s commitment to innovative research and discovery. We look forward to more fascinating discoveries coming out of our R&D colleagues’ exciting work and working with new and current partners to bring new medicine to patients worldwide.
It has been a challenging yet rewarding year. With this great news, I wish you a wonderful holiday season filled with warmth and joy!
https://lnkd.in/e6EPgvsy
I just registered for BIO-Europe, held in-person October 24-26, 2022 in Leipzig, Germany. Join me! https://lnkd.in/dM8KPS9a . Informa Connect
